The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam
-
Published:2024-03
Issue:3
Volume:20
Page:128-135
-
ISSN:2173-5743
-
Container-title:Reumatología Clínica (English Edition)
-
language:en
-
Short-container-title:Reumatología Clínica (English Edition)
Author:
Bui Hai-Binh,
Lai Hong-Thinh,
Nguyen Thanh-Lam,
Vu Thuy-Duong,
Bui Nhat-Le,
Nguyen Van-Hung,
Tran Thi-To-Chau,
Nguyen Thi-Phuong-Thuy,
Nguyen Thi-Ngoc-Lan,
Al-Tawfiq Jaffar A.,
Chu Dinh-ToiORCID
Reference44 articles.
1. One year in review 2019: pathogenesis of rheumatoid arthritis;Croia;Clin Exp Rheumatol,2019
2. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis;Lin;Cells,2020
3. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry;Bergstra;Ann Rheum Dis,2018
4. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland;Aaltonen;Scand J Rheumatol,2017
5. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system;Rashid;J Med Econ,2016